Advertisement


Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

2023 ASCO Annual Meeting

Advertisement

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to induction therapy with atezolizumab plus platinum and gemcitabine did not seem to impact overall survival for patients with metastatic urothelial carcinoma. Cisplatin-treated patients appeared to derive a greater benefit with atezolizumab than did carboplatin-treated patients (Abstract 4503).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Enrique Grande, MD: We are here presenting the post-hoc analysis of the IMvigor130 trial about the overall survival according to the response to the induction chemotherapy, based on platinum, that the patient received from this phase-3 trial. As a brief reminder, the IMvigor130 trial was a phase-3 trial, in first-line metastatic urothelial carcinoma patients that were randomized into one of these three arms: chemotherapy, platinum-based chemotherapy, cis/gem, carbo/gem, standard of care at that time; or chemotherapy plus atezolizumab; or another third arm with atezolizumab, the PD-L1 inhibitor, as a single agent. In this post-hoc analysis, we are as considering those patients who were randomized to one of the arms with chemotherapy. They should have received at least four cycles of chemotherapy, of platinum-based chemotherapy. They should have observed a clinical benefit during this induction chemotherapy. It means at least complete response, or partial response, or a stable disease for up to six months on treatment. And they should have also been treated with at least one cycle of maintenance therapy, either with atezolizumab or with placebo matching maintenance therapy. In terms of the overall survival that we got here, the overall survival was counting since week 18, the supposed day one, cycle six of the induction chemotherapy. We analyzed in a retrospective way, two populations: those with a clinical benefit, and those patients in the intention to treat population that progressed during induction chemotherapy. Of course, the prognosis was completely different in between these two populations. What were the main outcomes from this post-hoc analysis? The main outcomes that we observed is that unfortunately, we didn't observe significant difference, clinically speaking and statistically speaking, for those patients we received the combination of chemo plus atezo followed by atezo maintenance, versus those patients in terms of survival that received only chemotherapy. Hazard ratio was 0.84, and the median overall survival in the combination arm followed by the maintenance strategy was 20.5 months, versus 19.6 months in the standard arm. Those patients with the better prognosis, so it means those patients treated with cisplatin, gemcitabine, plus atezolizumab, and those patients with PD-L1 positive expression, they have better prognosis than those patients treated with carbo or those patients with a PD-L1 negative expression in the tumor. But if this is a matter of immunogenicity, we still don't know. We are working on that. The translational research is undergoing this sense. Maybe this is just a matter of prognosis. Another important outcome. What happened in those patients who progressed during the induction chemotherapy? This is the subgroup of patients with the poorest prognosis. The median overall survival for these patients progressing during chemo was only 3.3 months, despite more than 40% of the patients received subsequent lines of treatment, most of them immunotherapy or chemotherapy in the standard control arm. So, there is a clear unmet clinical need on this particular scenario, and it merits to think about if it deserves to give any systemic treatment options for these patients, or at least the current systemic options for these patients that we have so far. Last thing is that the use of enfortumab vedotin, or all their targeted agents like FDFR inhibitors, in this setting was negligible. Very few patients received that, so we cannot really extrapolate or make any conclusion about that. Thank you so much.

Related Videos

Gynecologic Cancers

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Mansoor R. Mirza, MD, of Denmark’s Rigshospitalet and Copenhagen University Hospital, discuss new findings on dostarlimab-gxly plus carboplatin/paclitaxel, which improved progression-free survival while maintaining health-related quality of life, further supporting its use as a standard of care in primary advanced or recurrent endometrial cancer (Abstract 5504).

Lymphoma

Jennifer L. Crombie, MD, on DLBCL: Real-World Outcomes With Novel Therapies in Relapsed or Refractory Disease

Jennifer L. Crombie, MD, of Dana-Farber Cancer Institute, discusses the historically poor outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Her study examined real-world data on the use of novel therapies in this population and found that outcomes with second- and third-line regimens of polatuzumab vedotin-piiq plus bendamustine and rituximab and tafasitamab plus lenalidomide remain suboptimal, with worse outcomes particularly after chimeric antigen receptor T-cell therapy (Abstract 7552).

Skin Cancer
Immunotherapy

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Adnan Khattak, MBBS, FRACP, PhD, of Australia’s Hollywood Private Hospital & Edith Cowan University, discuss the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone. These results provide further evidence that a personalized neoantigen approach is potentially beneficial (Abstract LBA9503).

Breast Cancer

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the chemotherapy-free patients treated with trastuzumab and pertuzumab, the 3-year invasive disease–free survival was 98.8%, with no distant metastases (Abstract LBA506).

Lung Cancer
Immunotherapy

Jonathan W. Riess, MD, on EGFR-Mutated Non–Small Cell Lung Cancer: What’s Next?

Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.

Advertisement

Advertisement




Advertisement